Editorial content Premium Content

Guided missiles: antibody–drug conjugates

Following on from the success of monoclonal antibodies in oncology, analysts predict big sales from antibody–drug conjugates, while advances in the underlying platforms continue to drive dealmaking.

Go to the profile of BioPharma Dealmakers
Sep 05, 2017
4
0

Please sign in or register for FREE

Register to BioPharma Dealmakers

From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.

Register

No comments yet.